MétaCan
Menu
Back to cohort
Record W2979778936 · doi:10.1093/ehjcvp/pvz048

P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects

2019· article· en· W2979778936 on OpenAlexaff
Ovidio De Filippo, Fabrizio D’Ascenzo, Sergio Raposeiras‐Roubín, Emad Abu‐Assi, Mattia Peyracchia, Pier Paolo Bocchino, Tim Kinnaird, Albert Ariza‐Solé, Christoph Liebetrau, Sergio Manzano‐Fernández, Giacomo Boccuzzi, Josè P.S. Henriques, Christian Templin, Stephen B. Wilton, Pierluigi Omedè, Lazar Velicki, Ioanna Xanthopoulou, Luís Cláudio Lemos Correia, Enrico Cerrato, Andrea Rognoni, Fabrizio Ugo, Iván J. Núñez‐Gil, Mario Iannaccone, Andrea Montabone, Salma Taha, Toshiharu Fujii, Alessandro Durante, Xiantao Song, Sebastiano Gili, Giulia Magnani, Ferdinando Varbella, Tetsuma Kawaji, Pedro Flores Blanco, Alberto Garay, Giorgio Quadri, Dimitrios Alexopoulos, Berenice Caneiro Queija, Zenon Huczek, Rafael Cobas Paz, José Ramón González‐Juanatey, M Cespon Fernandez, Shaoping Nie, Isabel Muñoz Pousa, Masa‐aki Kawashiri, Diego Gallo, Umberto Morbiducci, Federico Conrotto, Antonio Montefusco, Alberto Domínguez‐Rodríguez, Ángel López‐Cuenca, Ángel Cequier, Andrés Íñiguez, Tullio Usmiani, Mauro Rinaldi, Gaetano Maria De Ferrari

Bibliographic record

VenueEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2019
Typearticle
Languageen
FieldMedicine
TopicAntiplatelet Therapy and Cardiovascular Diseases
Canadian institutionsLibin Cardiovascular Institute of Alberta
Fundersnot available
KeywordsMedicineAcute coronary syndromeInternal medicineMyocardial infarctionHazard ratioPrasugrelRenal functionKidney diseaseTicagrelorClinical endpointCardiologyConfidence intervalClinical trial

Abstract

fetched live from OpenAlex

AIMS: The aim of the present study was to establish the safety and efficacy profile of prasugrel and ticagrelor in real-life acute coronary syndrome (ACS) patients with renal dysfunction. METHODS AND RESULTS: All consecutive patients from RENAMI (REgistry of New Antiplatelets in patients with Myocardial Infarction) and BLEEMACS (Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome) registries were stratified according to estimated glomerular filtration rate (eGFR) lower or greater than 60 mL/min/1.73 m2. Death and myocardial infarction (MI) were the primary efficacy endpoints. Major bleedings (MBs), defined as Bleeding Academic Research Consortium bleeding types 3 to 5, constituted the safety endpoint. A total of 19 255 patients were enrolled. Mean age was 63 ± 12; 14 892 (77.3%) were males. A total of 2490 (12.9%) patients had chronic kidney disease (CKD), defined as eGFR <60 mL/min/1.73 m2. Mean follow-up was 13 ± 5 months. Mortality was significantly higher in CKD patients (9.4% vs. 2.6%, P < 0.0001), as well as the incidence of reinfarction (5.8% vs. 2.9%, P < 0.0001) and MB (5.7% vs. 3%, P < 0.0001). At Cox multivariable analysis, potent P2Y12 inhibitors significantly reduced the mortality rate [hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.54-0.96; P = 0.006] and the risk of reinfarction (HR 0.53, 95% CI 0.30-0.95; P = 0.033) in CKD patients as compared to clopidogrel. The reduction of risk of reinfarction was confirmed in patients with preserved renal function. Potent P2Y12 inhibitors did not increase the risk of MB in CKD patients (HR 1.00, 95% CI 0.59-1.68; P = 0.985). CONCLUSION: In ACS patients with CKD, prasugrel and ticagrelor are associated with lower risk of death and recurrent MI without increasing the risk of MB.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.038
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.245
Teacher spread0.232 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations53
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart Journal - Cardiovascular PharmacotherapySame topicAntiplatelet Therapy and Cardiovascular DiseasesFrench-language works237,207